She began using Wegovy, the version of Ozempic approved for weight loss, after struggling with obesity. She reveals which foods to avoid on a GLP-1 and how to prevent muscle loss.

India's anti-obesity drug market is currently valued at Rs 3,000-3,500 crore & is projected to grow nearly eightfold by 2030, ...

Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge ...

With the weight-loss blockbuster drug Wegovy, now in India, renowned endocrinologist and diabetologist Dr. Ambrish Mithal ...

Danish pharma giant Novo Nordisk’s announcement comes months after the launch of another top selling obesity drug Mounjaro in India by US based pharma giant Eli Lilly & Company.

In a trial, the daily GLP-1 pill showed "significant" results and similar side effects to injectable GLP-1 drugs like Ozempic ...

Eli Lilly's orforglipron reduced A1C and weight in type 2 diabetes, while weekly insulin efsitora matched daily insulin with ...

The blockbuster weight loss drug, semaglutide, now has competition in orforglipron, which is just as safe as injectable ...

A first look at the phase 3 data with Eli Lilly's oral GLP-1 agonist orforglipron reveals encouraging blood sugar control ...

A new oral anti-diabetes pill, orforglipron, shows similar effectiveness to injectable GLP-1 drugs in a Phase 3 trial.

Over the next 12 years through NHS primary care providers, 1.6 million people are expected to receive tirzepatide, a weight ...